|
Apr 17
|
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
|
|
Apr 17
|
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
|
|
Apr 15
|
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
|
|
Apr 14
|
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
|
|
Apr 7
|
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
|
|
Apr 7
|
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
|
|
Apr 5
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan
|
|
Apr 5
|
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
|
|
Feb 24
|
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
|
|
Feb 24
|
Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
|
|
Feb 24
|
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
|
|
Feb 21
|
2 Healthcare Stocks with Big Upside and 1 to Skip
|
|
Feb 18
|
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
|
|
Feb 18
|
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
|
|
Feb 18
|
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
|
|
Feb 18
|
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
|
|
Feb 14
|
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
|
|
Feb 13
|
Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders
|
|
Feb 11
|
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
|
|
Feb 10
|
Regeneron’s macular oedema therapy shows promise in Phase III trial
|